Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib + Letrozole in HR+/HER2- Advanced Breast Cancer
NCT05337657Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lerociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Genor Biopharma. Primary endpoints: Dose-Limiting Toxicity and Adverse Events. Status: unknown.
02
Drugs
lerociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05337657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337657.